Singapore has approved Leqvio^® (inclisiran) from Novartis for the treatment of adults with hypercholesterolemia (increased blood cholesterol level) or mixed dyslipidemia (unhealthy levels of one or more kinds of fat in the blood).

Leqvio^® is an innovative small interfering RNA (siRNA), a type of molecule that aids to lower LDL-C level in the blood, as an add-on to existing cholesterol-lowering therapies and lifestyle modifications. This approval is based on the results of ORION-9, 10 and 11, a comprehensive clinical research program, where Leqvio^® provided an effective LDL-reduction of up to 52% in patients with elevated LDL-C, despite maximally tolerated cholesterol-lowering therapy.

With two maintenance doses a year (administered as an initial dose, another one at three months and then every six months thereafter) and providing effective LDL-C reduction, Leqvio^® works as a complement to cholesterol-lowering medication. As an injection administered by healthcare professionals, it may help with the adherence challenges commonly encountered with self-administered treatments.